Adjuvant libtayo® (cemiplimab) significantly improves disease-free survival (dfs) after surgery in high-risk cutaneous squamous cell carcinoma (cscc) in phase 3 trial

Primary endpoint of dfs met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk cscc after surgery compared to placebo

REGN Ratings Summary

REGN Quant Ranking